Amarin announces senior management changes

Connecticut firm appoints ceo, president and principal accountant

Amarin Corporation, a US clinical-stage biopharmaceutical company with a focus on cardiovascular disease, has appointed Joseph Zakrzewski as chief executive. He will continue to serve as chairman of the board.

Zakrzewski has more than 20 years of experience, including holding the position of chief operating officer of Reliant Pharmaceuticals when Omacor/Lovaza was developed and acquired in 2007 by GlaxoSmithKline. He was most recently chief executive of Xcellerex, a Massachusetts-based biotechnology company. Although he currently serves on the boards of directors and in other advisory roles for various companies, Amarin is his primary business commitment.

Additionally, John Thero has been promoted to Amarin’s president. Since November 2009, he has been the company’s chief financial officer.

Prior to joining Amarin, Thero was chief financial officer at ViaCell, where he helped guide the sale of the company, and Abiomed, during its transition from a development-stage company into a commercial entity.

Colin Stewart, who was Amarin’s president and ceo, resigned last month to address personal matters.

In connection with these changes, Frederick Ahlholm, vice president finance, has become the company’s principal accounting officer.

You may also like

Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Pharmaceutical

Astoriom acquires Precision Stability Storage, expanding sample management capabilities

The acquisition strengthens Astoriom’s stability storage capabilities to meet increasing demand across North America and offers reliable, compliant and accessible solutions to advance scientific discovery and product development
Manufacturing

Key factors in engineering a perfect vacuum drying cycle – from agitator stroke to cake height

Pharmaceuticals demand exceptional control at every stage of production to maintain product integrity and maximise recovery. Drying is particularly critical, as it determines how much material is recovered and whether key attributes like stability, crystal form, and residual solvent content remain within specification
Pharmaceutical

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Subscribe now